COVID-19 Research

VICTR named to key role to streamline COVID-19 research response

The Vanderbilt Institute for Clinical and Translational Research (VICTR) and RTI International, a non-profit clinical research organization based in North Carolina, have been named Administrative Coordinating Center (ACC) of a national effort to st

Initial COVID-19 testing data show impact in Nashville’s minority communities

Early data assessing the primary language of those who received COVID-19 tests at Vanderbilt University Medical Center, and tested positive, illustrates the disproportionate impact the pandemic is having on racial or ethnic communities. Of the first 18,491 patients tested for the novel coronavirus, 1,063 speak 37 languages other than English, according to analysis of electronic health records by VUMC’s Office of Health Equity. Although this group represents 5.7% of those tested, they are 19.4% of those positive and the highest number reside in two adjacent Nashville ZIP codes.

Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.

Multinational consortium reports COVID-19 impact on cancer patients

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

Study to determine rate of novel coronavirus infection in U.S. children

Researchers at Vanderbilt University Medical Center are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families. The study, named the HEROS (Human Epidemiology and Response to SARS-CoV-2) study and funded by the National Institute of Allergy and Infectious Diseases (NIAID), aims to gain insight into how many children ages 1 to 21 have been infected, the percentage of those infected who develop symptoms of COVID-19 and any differences in immune responses to the virus between children and adults within the same household.

Safeguarding opioids a concern as children may have more access with families at home due to COVID-19

Tennessee parents take steps to safeguard opioids at home, an important concern when children are spending more time indoors due to COVID-19 social distancing recommendations. More than 50% of parents who filled a prescription for an opioid in the past five years kept leftover medication in the home, according to poll results.

Study launched to test hydroxychloroquine as treatment for COVID-19

Faced with a global pandemic of a virus previously unknown to humans, Vanderbilt University Medical Center (VUMC) is leading a clinical trial to understand if hydroxychloroquine, a well-known drug used for malaria and rheumatologic conditions, is safe and effective in treating hospitalized adults with COVID-19.

Vanderbilt team develops COVID-19 predictive model for Tennessee

A team including health economists, epidemiologists and a biostatistician at Vanderbilt University Medical Center and Vanderbilt University are amassing and processing data to develop a complex predictive model of the spread of COVID-19 within Tennessee, with region-specific projections, as well as a model of projected resource use during response to the pandemic.

Study aims to shield health workers from COVID-19 infection

Vanderbilt University Medical Center is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.